Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Amarin Corporation plcNASDAQ: AMRN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $638K fell 12.6% year over year, ahead of the -103.3% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -12.6% holds above the trailing-twelve-month pace of -103.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 3.03M USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- +1.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.03M | +0.5% |
| FY2024 | 2024-12-31 | 3.01M | +1.2% |
| FY2023 | 2023-12-31 | 2.98M | -3.8% |
| FY2022 | 2022-12-31 | 3.09M | +8.3% |
| FY2021 | 2021-12-31 | 2.86M | — |
Depreciation & Amortization vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -103.3% is the lowest of 10, against a peer median of +14.4%.
- Depreciation & amortization amounts to 0.0% of revenue for AMRN, versus a peer median of 96.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +3.0% | 28.9% | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -11.2% | 33645.2% | |
| LTM Mar 2026 | $3.75M USD | -7.8% | +14.7% | 97.6% | |
| LTM Mar 2026 | $3.14M USD | +14181.8% | -37.6% | — | |
| LTM Dec 2025 | CHF 2.5M CHF | +15.5% | +0.4% | 69.9% | |
| LTM Mar 2026 | $885K USD | — | -2.3% | 96.0% | |
| LTM Mar 2026 | $674K USD | +14.4% | +24.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K USD | +79.6% | +28.8% | — |
| LTM Mar 2026 | $326K USD | +176.0% | — | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| LTM Mar 2026 | $97.21K USD | -103.3% | -0.7% | 0.0% | |
| Peer median (excluding AMRN) | — | +14.4% | +0.4% | 96.8% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.